Insulino‐mimetic and anti‐diabetic effects of vanadium compounds

Compounds of the trace element vanadium exert various insulin‐like effects in in vitro and in vivo systems. These include their ability to improve glucose homeostasis and insulin resistance in animal models of Type 1 and Type 2 diabetes mellitus. In addition to animal studies, several reports have documented improvements in liver and muscle insulin sensitivity in a limited number of patients with Type 2 diabetes. These effects are, however, not as dramatic as those observed in animal experiments, probably because lower doses of vanadium were used and the duration of therapy was short in human studies as compared with animal work. The ability of these compounds to stimulate glucose uptake, glycogen and lipid synthesis in muscle, adipose and hepatic tissues and to inhibit gluconeogenesis, and the activities of the gluconeogenic enzymes: phosphoenol pyruvate carboxykinase and glucose‐6‐phosphatase in the liver and kidney as well as lipolysis in fat cells contributes as potential mechanisms to their anti‐diabetic insulin‐like effects. At the cellular level, vanadium activates several key elements of the insulin signal transduction pathway, such as the tyrosine phosphorylation of insulin receptor substrate‐1, and extracellular signal‐regulated kinase 1 and 2, phosphatidylinositol 3‐kinase and protein kinase B activation. These pathways are believed to mediate the metabolic actions of insulin. Because protein tyrosine phosphatases (PTPases) are considered to be negative regulators of the insulin‐signalling pathway, it is suggested that vanadium can enhance insulin signalling and action by virtue of its capacity to inhibit PTPase activity and increase tyrosine phosphorylation of substrate proteins. There are some concerns about the potential toxicity of available inorganic vanadium salts at higher doses and during long‐term therapy. Therefore, new organo‐vanadium compounds with higher potency and less toxicity need to be evaluated for their efficacy as potential treatment of human diabetes.

[1]  J. Domingo Vanadium and tungsten derivatives as antidiabetic agents , 2002, Biological Trace Element Research.

[2]  S. Pugazhenthi,et al.  Does the insulin-mimetic action of vanadate involve insulin receptor kinase? , 1993, Molecular and Cellular Biochemistry.

[3]  S. Semiz,et al.  Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity , 2002, Molecular and Cellular Biochemistry.

[4]  J. McNeill,et al.  Vanadium increases GLUT4 in diabetic rat skeletal muscle , 2002, Molecular and Cellular Biochemistry.

[5]  S. Semiz,et al.  Effects of diabetes, vanadium, and insulin on glycogen synthase activation in Wistar rats , 2002, Molecular and Cellular Biochemistry.

[6]  S. Bhanot,et al.  In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats , 2001, Molecular and Cellular Biochemistry.

[7]  S. Bhanot,et al.  In vivo effects of vanadium in diabetic rats are independent of changes in PI‐3 kinase activity in skeletal muscle , 2001, Molecular and Cellular Biochemistry.

[8]  A. Lochner,et al.  Effect of Vanadate and Insulin on Glucose Transport in Isolated Adult Rat Cardiomyocytes , 2000, Cardiovascular Drugs and Therapy.

[9]  A. Srivastava Anti-diabetic and toxic effects of vanadium compounds , 2000, Molecular and Cellular Biochemistry.

[10]  J. McNeill,et al.  Vanadium and diabetes , 1998, Molecular and Cellular Biochemistry.

[11]  S. Pandey,et al.  Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin , 1998, Molecular and Cellular Biochemistry.

[12]  M. White,et al.  The IRS-signalling system: A network of docking proteins that mediate insulin action , 1998, Molecular and Cellular Biochemistry.

[13]  J. Domingo,et al.  Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation , 1995, Molecular and Cellular Biochemistry.

[14]  C. Kahn,et al.  In vivo andin vitro studies of vanadate in human and rodent diabetes mellitus , 1995, Molecular and Cellular Biochemistry.

[15]  Han‐Chung Wang,et al.  Unique and selective mitogenic effects of vanadate on SV40-transformed cells , 1995, Molecular and Cellular Biochemistry.

[16]  S. Pugazhenthi,et al.  Decrease in protein tyrosine phosphatase activities in vanadate-treated obese Zucker (fa/fa) rat liver , 1995, Molecular and Cellular Biochemistry.

[17]  S. Pugazhenthi,et al.  In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals , 1995, Molecular and Cellular Biochemistry.

[18]  S. Pugazhenthi,et al.  Effects of high sucrose diet on insulin-like effects of vanadate in diabetic rats , 1993, Molecular and Cellular Biochemistry.

[19]  S. Pugazhenthi,et al.  Effects of vanadate administration on the high sucrose diet-induced aberrations in normal rats , 1993, Molecular and Cellular Biochemistry.

[20]  R. Sargeant,et al.  Vanadate induces the recruitment of glut-4 glucose transporter to the plasma membrane of rat adipocytes , 1992, Molecular and Cellular Biochemistry.

[21]  O. Blondel,et al.  In vivo insulin resistance in streptozotocin-diabetic rats — evidence for reversal following oral vanadate treatment , 1989, Diabetologia.

[22]  J. McNeill,et al.  In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats , 2004, Molecular and Cellular Biochemistry.

[23]  J. McNeill,et al.  Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo , 2004, Molecular and Cellular Biochemistry.

[24]  I. G. Fantus,et al.  Multifunctional actions of vanadium compounds on insulin signaling pathways: Evidence for preferential enhancement of metabolic versus mitogenic effects , 1998, Molecular and Cellular Biochemistry.

[25]  S. Brichard Outlook of diabetes treatment possibilities with vanadium and other metal salts , 2003 .

[26]  J. McNeill,et al.  Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo. , 2002, Endocrinology.

[27]  M. White,et al.  IRS proteins and the common path to diabetes. , 2002, American journal of physiology. Endocrinology and metabolism.

[28]  J. Waring,et al.  PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Goldstein Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. , 2002, The Journal of clinical endocrinology and metabolism.

[30]  A. Kiersztan,et al.  Inhibition of gluconeogenesis by vanadium and metformin in kidney-cortex tubules isolated from control and diabetic rabbits. , 2002, Biochemical pharmacology.

[31]  B. Monia,et al.  Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. , 2002, Diabetes.

[32]  J. Molero,et al.  Activation of MAP kinase by insulin and vanadate in adipocytes from young and old rats , 2002, Molecular and Cellular Endocrinology.

[33]  K. Goa,et al.  Rosiglitazone , 2012, Drugs.

[34]  José L Domingo,et al.  Vanadium and tungsten derivatives as antidiabetic agents: a review of their toxic effects. , 2002, Biological trace element research.

[35]  D. Accili,et al.  The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. , 2001, The Journal of clinical investigation.

[36]  J. McNeill,et al.  Effect of vanadium on insulin sensitivity and appetite. , 2001, Metabolism: clinical and experimental.

[37]  P. Lochhead,et al.  Inhibition of GSK-3 Selectively Reduces Glucose-6-Phosphatase and Phosphoenolpyruvate Carboxykinase Gene Expression , 2001 .

[38]  É. Hajduch,et al.  Protein kinase B (PKB/Akt) – a key regulator of glucose transport? , 2001, FEBS letters.

[39]  R. DeFronzo,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society COMMENT Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes* , 2022 .

[40]  J. Hardman,et al.  Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas , 2001 .

[41]  M. Khamaisi,et al.  Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil , 2001, Diabetes/metabolism research and reviews.

[42]  J. McNeill,et al.  Mechanisms of vanadium action: insulin-mimetic or insulin-enhancing agent? , 2000, Canadian journal of physiology and pharmacology.

[43]  Y. Shechter,et al.  Organic vanadium chelators potentiate vanadium-evoked glucose metabolism in vitro and in vivo: establishing criteria for optimal chelators. , 2000, Molecular pharmacology.

[44]  J. Olefsky Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .

[45]  H. Sakurai,et al.  Evidence for the Improvement of Noninsulin‐Dependent Diabetes Mellitus in KKAy Mice with Daily Oral Administration of Bis(6‐methylpicolinato)oxovanadium(IV) Complex. , 2000 .

[46]  M. Shefi,et al.  Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vandadate treatment on hepatic glucose-6-phoshatase and phosphoenolpyruvate carboxykinase. , 2000, Metabolism: clinical and experimental.

[47]  C. Kahn,et al.  Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. , 2000, Metabolism: clinical and experimental.

[48]  J. Olefsky Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. , 2000, The Journal of clinical investigation.

[49]  A. Tracey,et al.  Bis(N,N-dimethylhydroxamido)hydroxooxovanadate inhibition of protein tyrosine phosphatase activity in intact cells: comparison with vanadate. , 1999, Biochemical pharmacology.

[50]  H. Sakurai,et al.  Evidence for the improvement of noninsulin-dependent diabetes mellitus in KKAy mice with daily oral administration of bis(6-methylpicolinato)oxovanadium(IV) complex. , 1999, Chemical & pharmaceutical bulletin.

[51]  M. Bernier,et al.  Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate. , 1999, Biochemistry.

[52]  P. Cohen,et al.  Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B* , 1999, The Journal of Biological Chemistry.

[53]  D. Accili,et al.  Insulin Stimulates Phosphorylation of the Forkhead Transcription Factor FKHR on Serine 253 through a Wortmannin-sensitive Pathway* , 1999, The Journal of Biological Chemistry.

[54]  Feng Liu,et al.  Primary Structure, Tissue Distribution, and Expression of Mouse Phosphoinositide-dependent Protein Kinase-1, a Protein Kinase That Phosphorylates and Activates Protein Kinase Cζ* , 1999, The Journal of Biological Chemistry.

[55]  Independent signal-transduction pathways for vanadate and for insulin in the activation of glycogen synthase and glycogenesis in rat adipocytes. , 1999, Endocrinology.

[56]  S. Brichard,et al.  Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats , 1999, British journal of pharmacology.

[57]  M. Battell,et al.  Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats. , 1999, Diabetes research and clinical practice.

[58]  I. G. Fantus,et al.  Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. , 1998, Diabetes.

[59]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[60]  A. Evangelou,et al.  Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo(alpha)pyrene-induced leiomyosarcomas in Wistar rats. , 1998, Anticancer research.

[61]  K. Siddle,et al.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. , 1998, The Biochemical journal.

[62]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[63]  Vanadyl sulfate-stimulated glycogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation. , 1998, Biochemistry.

[64]  Y. Shechter,et al.  Vanadate elevates lipogenicity of starved rat adipose tissue: mechanism of action. , 1998, Endocrinology.

[65]  J. Downward Mechanisms and consequences of activation of protein kinase B/Akt. , 1998, Current opinion in cell biology.

[66]  B. Spiegelman PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[67]  J. Molero,et al.  Vanadate fully stimulates insulin receptor substrate‐1 associated phosphatidyl inositol 3‐kinase activity in adipocytes from young and old rats , 1998, FEBS letters.

[68]  J. Domingo,et al.  Effects of Vanadium on Activity and Learning in Rats , 1998, Physiology & Behavior.

[69]  E. Ziv,et al.  Cellular Mechanism of Nutritionally Induced Insulin Resistance: The Desert Rodent Psammomys obesus and Other Animals in which Insulin Resistance leads to Detrimental Outcome , 1998, Journal of basic and clinical physiology and pharmacology.

[70]  G. Elberg,et al.  Vanadate Activates Membranous Nonreceptor Protein Tyrosine Kinase in Rat Adipocytes , 1997, Diabetes.

[71]  G. Dohm,et al.  Vanadate stimulation of 2-deoxyglucose transport is not mediated by PI 3-kinase in human skeletal muscle. , 1997, Biochimica et biophysica acta.

[72]  F. Romano,et al.  Effects of oral vanadyl treatment on diabetes-induced alterations in the heart GLUT-4 transporter. , 1997, Journal of molecular and cellular cardiology.

[73]  I. G. Fantus,et al.  Vanadium Compounds Biological Actions and Potential as Pharmacological Agents , 1997, Trends in Endocrinology & Metabolism.

[74]  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Antilipolytic Actions of Vanadate and Insulin in Rat Adipocytes Mediated by Distinctly Different Mechanisms* , 2022 .

[75]  S. Pugazhenthi,et al.  Inhibition of a Src homology 2 domain containing protein tyrosine phosphatase by vanadate in the primary culture of hepatocytes. , 1996, Archives of biochemistry and biophysics.

[76]  W. Waldhäusl,et al.  Insulin-like vs. non-insulin-like stimulation of glucose metabolism by vanadium, tungsten, and selenium compounds in rat muscle. , 1996, Life sciences.

[77]  G. Boden,et al.  Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. , 1996, Metabolism: clinical and experimental.

[78]  R. Pederson,et al.  Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. , 1996, Canadian journal of physiology and pharmacology.

[79]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[80]  B. Posner,et al.  Arrest at the G2/M transition of the cell cycle by protein‐tyrosine phosphatase inhibition: Studies on a neuronal and a glial cell line , 1995, Journal of cellular biochemistry.

[81]  C. Kahn,et al.  Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. , 1995, The Journal of clinical endocrinology and metabolism.

[82]  B. Posner,et al.  Hypoglycemic Effects of Peroxovanadium Compounds in Sprague-Dawley and Diabetic BB Rats , 1995, Diabetes.

[83]  A. Srivastava Section Review—Oncologic, Endocrine & Metabolic: Potential Use of Vanadium Compounds in the Treatment of Diabetes Mellitus , 1995 .

[84]  G. Dohm,et al.  Okadaic Acid, Vanadate, and Phenylarsine Oxide Stimulate 2-Deoxyglucose Transport in Insulin-Resistant Human Skeletal Muscle , 1995, Diabetes.

[85]  H. Shamoon,et al.  Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.

[86]  C. Djordjevic Antitumor activity of vanadium compounds. , 1995, Metal ions in biological systems.

[87]  J. Berger,et al.  PI 3-kinase activation is required for insulin stimulation of glucose transport into L6 myotubes. , 1994, Biochemical and biophysical research communications.

[88]  B. Harland,et al.  Is vanadium of human nutritional importance yet? , 1994, Journal of the American Dietetic Association.

[89]  J. Henquin,et al.  Comparison of the effects of various vanadium salts on glucose homeostasis in streptozotocin-diabetic rats. , 1994, European journal of pharmacology.

[90]  A. Srivastava,et al.  Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation , 1994, FEBS letters.

[91]  I. G. Fantus,et al.  Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. , 1994, The Journal of biological chemistry.

[92]  C. Kahn,et al.  The insulin signaling system. , 1994, The Journal of biological chemistry.

[93]  H. McCarthy,et al.  Effects of Chronic Vanadate Administration in the STZ-Induced Diabetic Rat: The Antihyperglycemic Action of Vanadate Is Attributable Entirely to Its Suppression of Feeding , 1994, Diabetes.

[94]  A. Shisheva,et al.  The protein tyrosine phosphatase inhibitor, pervanadate, is a powerful antidiabetic agent in streptozotocin-treated diabetic rats. , 1994, Endocrinology.

[95]  F. Bosch,et al.  Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats. , 1993, The Journal of clinical investigation.

[96]  A. Shisheva,et al.  Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. , 1993, The Journal of biological chemistry.

[97]  J. McNeill,et al.  Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). , 1993, Canadian journal of physiology and pharmacology.

[98]  J. McNeill,et al.  Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). , 1993, Canadian journal of physiology and pharmacology.

[99]  J. Girard,et al.  Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: Effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT2 , 1993, Molecular and Cellular Endocrinology.

[100]  P. J. Jones,et al.  Role of vanadium in nutrition: metabolism, essentiality and dietary considerations. , 1993, Life sciences.

[101]  C. Kahn,et al.  Insulin differentially regulates protein phosphotyrosine phosphatase activity in rat hepatoma cells. , 1992, Biochemistry.

[102]  J. Tavaré,et al.  Characterization of insulin-stimulated protein serine/threonine kinases in CHO cells expressing human insulin receptors with point and deletion mutations. , 1992, The Biochemical journal.

[103]  A. Shisheva,et al.  Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. , 1992, Biochemistry.

[104]  S. Brichard,et al.  Vanadate treatment markedly increases glucose utilization in muscle of insulin-resistant fa/fa rats without modifying glucose transporter expression. , 1992, Endocrinology.

[105]  C. Bailey Biguanides and NIDDM , 1992, Diabetes Care.

[106]  L. Groop Sulfonylureas in NIDDM , 1992, Diabetes Care.

[107]  J. McNeill,et al.  Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. , 1992, Journal of medicinal chemistry.

[108]  F. Bosch,et al.  Activation by Vanadate of Glycolysis in Hepatocytes From Diabetic Rats , 1991, Diabetes.

[109]  S. Pugazhenthi,et al.  Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. , 1991, Metabolism: clinical and experimental.

[110]  Y. Shechter,et al.  Vanadate inhibits glucose output from isolated perfused rat liver , 1991, Hepatology.

[111]  S. Pugazhenthi,et al.  Insulin-like effect of vanadate on malic enzyme and glucose-6-phosphate dehydrogenase activities in streptozotocin-induced diabetic rat liver. , 1991, Biochimica et biophysica acta.

[112]  H. Lodish,et al.  Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle of diabetic rats. , 1991, The Journal of clinical investigation.

[113]  M. Davidson,et al.  Antidiabetic Action of Vanadyl in Rats Independent of in Vivo Insulin-Receptor Kinase Activity , 1991, Diabetes.

[114]  C. Kahn,et al.  Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. , 1991, The Journal of clinical investigation.

[115]  S. Brichard,et al.  Marked Improvement of Glucose Homeostasis in Diabetic ob/ob Mice Given Oral Vanadate , 1990, Diabetes.

[116]  J. McNeill,et al.  Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology. , 1990, Pharmacology & toxicology.

[117]  M. Permutt,et al.  Effects of altered glucose homeostasis on glucose transporter expression in skeletal muscle of the rat. , 1990, The Journal of clinical investigation.

[118]  W. M. Sherman,et al.  Exercise training increases glucose transporter protein GLUT‐4 in skeletal muscle of obese Zucker (fa/fa) rats , 1990, FEBS letters.

[119]  S. Pugazhenthi,et al.  Insulinlike Effects of Vanadate on Hepatic Glycogen Metabolism in Nondiabetic and Streptozocin-Induced Diabetic Rats , 1990, Diabetes.

[120]  J. Berger,et al.  Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin-responsive glucose transporter in skeletal muscle. , 1990, Endocrinology.

[121]  J. McNeill,et al.  Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin. , 1990, Canadian journal of physiology and pharmacology.

[122]  J. Simon,et al.  Impaired insulin action but normal insulin receptor activity in diabetic rat liver: effect of vanadate. , 1990, The American journal of physiology.

[123]  M. Permutt,et al.  Glucose transporter levels in spontaneously obese (db/db) insulin-resistant mice. , 1990, The Journal of clinical investigation.

[124]  Y. Shechter Insulin-Mimetic Effects of Vanadate: Possible Implications for Future Treatment of Diabetes , 1990, Diabetes.

[125]  S. Brichard,et al.  Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. , 1989, Endocrinology.

[126]  R. Pederson,et al.  Long-Term Effects of Vanadyl Treatment on Streptozocin-Induced Diabetes in Rats , 1989, Diabetes.

[127]  I. G. Fantus,et al.  Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. , 1989, Biochemistry.

[128]  L. Rossetti,et al.  Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. , 1989, The Journal of clinical investigation.

[129]  C. Kahn,et al.  Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats. , 1989, The Journal of clinical investigation.

[130]  P. Vicario,et al.  The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo. , 1989, Endocrinology.

[131]  J. Meyerovitch,et al.  Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. , 1987, The Journal of biological chemistry.

[132]  A. Ullrich,et al.  Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. , 1987, The Journal of biological chemistry.

[133]  J. K. Grady,et al.  Vanadium complexes of transferrin and ferritin in the rat. , 1986, Biochimica et biophysica acta.

[134]  A. Green The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. , 1986, The Biochemical journal.

[135]  W. Mitch,et al.  Selectivity of the insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle. , 1985, The Biochemical journal.

[136]  J. McNeill,et al.  Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. , 1985, Science.

[137]  M. Olive,et al.  Lipid synthesis in isolated rat hepatocytes: activation by insulin and vanadate and inhibition by ouabain. , 1984, Biochemistry international.

[138]  S. Tamura,et al.  A novel mechanism for the insulin-like effect of vanadate on glycogen synthase in rat adipocytes. , 1984, The Journal of biological chemistry.

[139]  B. R. Nechay Mechanisms of action of vanadium. , 1984, Annual review of pharmacology and toxicology.

[140]  N. Chasteen The biochemistry of vanadium , 1983 .

[141]  G. Swarup,et al.  Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. , 1982, Biochemical and biophysical research communications.

[142]  R. C. Nordlie,et al.  Vanadate: a potent inhibitor of multifunctional glucose-6-phosphatase. , 1981, Biochimica et biophysica acta.

[143]  H. Degani,et al.  Electron paramagnetic resonance studies and insulin-like effects of vanadium in rat adipocytes. , 1981, Biochemistry.

[144]  T. Clausen,et al.  The relationship between the transport of glucose and cations across cell membranes in isolated tissues. XI. The effect of vanadate on 45Ca-efflux and sugar transport in adipose tissue and skeletal muscle. , 1981, Biochimica et biophysica acta.

[145]  F. L. Crane,et al.  Does vanadium play a role in cellular regulation? , 1981, Current topics in cellular regulation.

[146]  G. Dubyak,et al.  The insulin-mimetic effects of vanadate in isolated rat adipocytes. Dissociation from effects of vanadate as a (Na+-K+)ATPase inhibitor. , 1980, The Journal of biological chemistry.

[147]  F. L. Crane,et al.  Vanadate inhibits mevalonate synthesis and activates NADH oxidation in microsomes , 1980, FEBS letters.

[148]  Y. Shechter,et al.  Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions , 1980, Nature.

[149]  A. Pansini,et al.  Effects of vanadium on glucose metabolism in vitro. , 1979, Life sciences.

[150]  A. R. Byrne,et al.  Vanadium in foods and in human body fluids and tissues. , 1978, The Science of the total environment.

[151]  D. Azarnoff,et al.  Effect of cholesterol synthesis inhibition in normocholesteremic young men. , 1959, The Journal of clinical investigation.

[152]  D. Azarnoff,et al.  SITE OF VANADIUM INHIBITION OF CHOLESTEROL BIOSYNTHESIS , 1957 .